John Braswell, MD
Interventional Pain Medicine · Baton Rouge, LANPI 1164493458
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,280 of the $7,986 with a category attached, or 66.1%. 28 manufacturers reported payments, led by Abbott at 28.8% of the total. Reporting peaked in 2019 at $2,851 and has fallen 54.1% since, to $1,309 in 2025.
Across 295 payments — averaging $27.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Vertiflex, Inc.$2K
- Stryker$915
- Boston Scientific$438
- Si-bone, Inc.$313
- Medtronic$272
- plus $2K from 22 others
What the payments were for
- Travel & lodging$2,70534%
- Food & beverage$5,28066%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 160 | $2,298 |
| Vertiflex, Inc. | 10 | $2,213 |
| Stryker | 3 | $915 |
| Boston Scientific | 19 | $438 |
| Si-bone, Inc. | 3 | $313 |
| Medtronic(2 entities) | 13 | $272 |
| Collegium Pharmaceutical, Inc. | 13 | $249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $214 |
| Amgen | 12 | $183 |
| Saluda Medical Americas, Inc. | 3 | $158 |
| AbbVie(2 entities) | 9 | $133 |
| Novartis | 7 | $99 |
| Nevro Corp. | 5 | $74 |
| Valinor Pharma, LLC | 3 | $53 |
| Almatica Pharma LLC | 3 | $49 |
| Scilex Pharmaceuticals Inc. | 3 | $49 |
| MDD US Operations, LLC | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Globus Medical | 1 | $33 |
| Averitas Pharma Inc. | 1 | $21 |
| Nalu Medical, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Sentynl Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion ISS$1,991
- mild Device Kit$781
- Proclaim Family of SCS IPGs$284
- ETERNA$227
- PROCLAIM$144
- iFuse Implant$115
How this compares
$7,986 in reported general payments places this provider in the 60th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 4,164 | $95,008 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,493 | $81,839 |
| BelbucaBuprenorphine Hcl | 84 | $74,571 |
| Xtampza ErOxycodone Myristate | 98 | $70,149 |
| MovantikNaloxegol Oxalate | 88 | $39,958 |
| OxycontinOxycodone Hcl | 51 | $37,675 |
| Oxymorphone Hcl ErOxymorphone Hcl | 20 | $22,007 |
| Buprenorphine | 50 | $15,148 |
| Gabapentin | 1,328 | $15,084 |
| NucyntaTapentadol Hcl | 13 | $13,418 |
| Oxycodone Hcl | 559 | $12,240 |
| Fentanyl | 112 | $10,930 |
| Tizanidine Hcl | 959 | $9,434 |
| Morphine Sulfate ErMorphine Sulfate | 318 | $9,126 |
| Lidocaine | 72 | $8,248 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $249 | $158,139195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 57 interventional pain medicine providers in Louisiana.
Other interventional pain medicine in Baton Rouge
- Adam CarinciBaton Rouge$17K
- Jihad JihaBaton Rouge$17K
- Kelly BoussertBaton Rouge$9K
- Gary McDanielBaton Rouge$9K
- Sean GrahamBaton Rouge$5K
- John CrosbyBaton Rouge$5K
- Alpesh PatelBaton Rouge$4K
- Joseph TurnipseedBaton Rouge$4K
- Allison WalkerBaton Rouge$2K
- John BurdineBaton Rouge$177
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.